Allergan’s boss Brent Saunders said that the company plans to increase dividend on an annual basis over time.
“We also retain firepower to continue strengthening our growth through investment in accretive transactions and stepping stone R&D deals,” said Saunders, Chairman, CEO and President .
The first first quarter 2017 dividend will be paid in the end of March, Allergan said praising its long term business strategy.
Allergan on Wednesday completed the $2.9 billion purchase of Acelity’s subsidiary LifeCell, and thus added LifeCell’s commercial products to its regenerative medicine portfolio, as well as its manufacturing capabilities and its R&D operations, based in New Jersey.